A director at Atos SE bought 500 shares at 50.800EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
A director at UCB SA bought 70 shares at 250.000EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...
Unibail-Rodamco-Westfield sets CEO succession in 2026 Paris, October 23, 2025 Press release Unibail-Rodamco-Westfield sets CEO succession in 2026 Vincent Rouget, currently Chief Strategy & Investment Officer and acting as COO Europe, appointed CEO and Chairman of the Management Board as from January 1, 2026 Decision reflects the strong position of the business and positive trajectory under ‘A Platform for Growth’ 2025-28 business plan, established by Jean-Marie Tritant, CEO and Chairman of the Management Board since 2021, who will lead the transition through the end of the year ...
UNIBAIL-RODAMCO-WESTFIELD Q3-2025 TRADING UPDATE Paris, October 23, 2025 Press release UNIBAIL-RODAMCO-WESTFIELD Q3-2025 TRADING UPDATE UPGRADED GUIDANCE AND FLAGSHIP ASSET ACQUISITION ADVANCING ‘A PLATFORM FOR GROWTH’ 2025–28 PLAN Solid operating performance in 9M-2025 Tenant sales up +3.4%1 and footfall up +1.8% MGR uplift of +6.7% on top of indexed passing rents+11.0% increase in signed rent per sqm, showing focus on high value leasesLike-for-like Shopping Centres GRI up +2.4%, consistent with H1-2025 Complete delivery in September of Coppermaker Square residential scheme in ...
Transformation Gaining Momentum in Q3 2025 with Estimated Net Change in Cash Limited to €-38m FY25 Profitability and Cash Targets Confirmed as the Genesis Plan Progresses Steadily Press Release Transformation Gaining Momentum in Q3 2025 with Estimated Net Change in Cash Limited to €-38m FY25 Profitability and Cash Targets Confirmed as the Genesis Plan Progresses Steadily Q3 2025 estimated net change in cash1 limited to c. €-38 million Delivered without any usage of account receivable factoring or specific optimization on trade payablesIncluding restructuring impact in Q3 2025 (est. at...
La transformation s’accélère au troisième trimestre 2025 avec une variation nette de trésorerie estimée à seulement -38 millions d’euros Les objectifs de rentabilité et de génération de trésorerie sont confirmés pour l’exercice 2025 Communiqué de presse La transformation s’accélère au troisième trimestre 2025 avec une variation nette de trésorerie estimée à seulement -38 millions d’euros Les objectifs de rentabilité et de génération de trésorerie sont confirmés pour l’exercice 2025 tandis que l’exécution du plan Genesis se poursuit à un rythme soutenu Variation nette de trésorerie1 ...
UCB announced that the final analysis of an open-label extension (OLE) study on Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS) was published in the Epilepsy and Behavior journal. This follows previous presentations at a medical conference and highlights the long-term sustained benefit and lack of new or unexpected safety signals, which we view as supportive of Fintepla's benefit in this patient population. For reference, Fintepla is one of UCB's 5 growth drivers, and we estimate peak s...
UCB announced the publication of results from a multicenter retrospective chart review study of pyrimidine nucleo(s)(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) in Neurology, which are in line with previous reports of the positive outcomes on survival and functional outcomes presented at a medical conference earlier this year. Note that TK2d is an ultra-rare genetic mitochondrial disease with no approved therapies, and has a prevalence of 1.64 per 1m people. Doxecitine an...
URW SE - Information on total number of voting rights and shares in the share capital as at September 30, 2025 Paris, October 2nd, 2025 Information on total number of voting rights and shares in the share capital as of September 30th, 2025 (Article L.233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the AMF) DateTotal number of shares in the capitalTotal number of voting rights30/09/2025143,307,562143,307,562 UNIBAIL-RODAMCO-WESTFIELD SEA European Company with Management Board and Supervisory BoardShare capital: €716,223,635Registered office: 7 place d...
URW SE - Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 30 septembre 2025 Paris, le 2 octobre 2025 Informations relatives au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2025 (articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’AMF) DateNombre total d’actions composant le capitalNombre total de droits de vote30/09/2025143 307 562143 307 562 UNIBAIL-RODAMCO-WESTFIELD SESociété Européenne à Directoire et Conseil de surveillanceau capital de 716 223 635 euros Si...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.